nodes	percent_of_prediction	percent_of_DWPC	metapath
Everolimus—Vitamin B12 deficiency—Metformin—polycystic ovary syndrome	0.0498	0.15	CcSEcCtD
Everolimus—Viral diarrhoea—Metformin—polycystic ovary syndrome	0.02	0.0604	CcSEcCtD
Everolimus—MTOR—embryo—polycystic ovary syndrome	0.0142	0.0822	CbGeAlD
Everolimus—CYP3A4—urine—polycystic ovary syndrome	0.0129	0.0747	CbGeAlD
Everolimus—Sinus congestion—Metformin—polycystic ovary syndrome	0.0105	0.0317	CcSEcCtD
Everolimus—FKBP1A—adrenal cortex—polycystic ovary syndrome	0.0105	0.0606	CbGeAlD
Everolimus—MTOR—endometrium—polycystic ovary syndrome	0.0104	0.0602	CbGeAlD
Everolimus—Epigastric discomfort—Metformin—polycystic ovary syndrome	0.00994	0.03	CcSEcCtD
Everolimus—Azotaemia—Metformin—polycystic ovary syndrome	0.00981	0.0296	CcSEcCtD
Everolimus—MTOR—uterus—polycystic ovary syndrome	0.00958	0.0554	CbGeAlD
Everolimus—Acidosis—Metformin—polycystic ovary syndrome	0.00944	0.0285	CcSEcCtD
Everolimus—MTOR—pituitary gland—polycystic ovary syndrome	0.00941	0.0544	CbGeAlD
Everolimus—MTOR—adipose tissue—polycystic ovary syndrome	0.00937	0.0542	CbGeAlD
Everolimus—FKBP1A—endometrium—polycystic ovary syndrome	0.00936	0.0541	CbGeAlD
Everolimus—FKBP1A—uterus—polycystic ovary syndrome	0.00862	0.0499	CbGeAlD
Everolimus—FKBP1A—pituitary gland—polycystic ovary syndrome	0.00847	0.049	CbGeAlD
Everolimus—FKBP1A—adipose tissue—polycystic ovary syndrome	0.00843	0.0488	CbGeAlD
Everolimus—MTOR—adrenal gland—polycystic ovary syndrome	0.00841	0.0486	CbGeAlD
Everolimus—Respiratory distress—Metformin—polycystic ovary syndrome	0.00823	0.0248	CcSEcCtD
Everolimus—Nail disorder—Metformin—polycystic ovary syndrome	0.00806	0.0243	CcSEcCtD
Everolimus—MTOR—female gonad—polycystic ovary syndrome	0.00784	0.0453	CbGeAlD
Everolimus—MTOR—vagina—polycystic ovary syndrome	0.00779	0.0451	CbGeAlD
Everolimus—FKBP1A—adrenal gland—polycystic ovary syndrome	0.00756	0.0437	CbGeAlD
Everolimus—MTOR—endocrine gland—polycystic ovary syndrome	0.00729	0.0422	CbGeAlD
Everolimus—FKBP1A—female gonad—polycystic ovary syndrome	0.00705	0.0408	CbGeAlD
Everolimus—FKBP1A—vagina—polycystic ovary syndrome	0.00701	0.0405	CbGeAlD
Everolimus—Fungal infection—Metformin—polycystic ovary syndrome	0.00677	0.0204	CcSEcCtD
Everolimus—FKBP1A—endocrine gland—polycystic ovary syndrome	0.00656	0.0379	CbGeAlD
Everolimus—Rhinorrhoea—Metformin—polycystic ovary syndrome	0.00645	0.0194	CcSEcCtD
Everolimus—Blood disorder—Metformin—polycystic ovary syndrome	0.00626	0.0189	CcSEcCtD
Everolimus—Chest discomfort—Metformin—polycystic ovary syndrome	0.00591	0.0178	CcSEcCtD
Everolimus—Nasal congestion—Metformin—polycystic ovary syndrome	0.00416	0.0126	CcSEcCtD
Everolimus—Renal impairment—Metformin—polycystic ovary syndrome	0.00399	0.012	CcSEcCtD
Everolimus—Hypoglycaemia—Metformin—polycystic ovary syndrome	0.00389	0.0117	CcSEcCtD
Everolimus—Lethargy—Metformin—polycystic ovary syndrome	0.00387	0.0117	CcSEcCtD
Everolimus—Pain in extremity—Metformin—polycystic ovary syndrome	0.00379	0.0114	CcSEcCtD
Everolimus—Migraine—Metformin—polycystic ovary syndrome	0.00373	0.0113	CcSEcCtD
Everolimus—Dehydration—Metformin—polycystic ovary syndrome	0.00353	0.0106	CcSEcCtD
Everolimus—Liver function test abnormal—Metformin—polycystic ovary syndrome	0.0035	0.0106	CcSEcCtD
Everolimus—Abdominal pain upper—Metformin—polycystic ovary syndrome	0.00347	0.0104	CcSEcCtD
Everolimus—Breast disorder—Metformin—polycystic ovary syndrome	0.00343	0.0103	CcSEcCtD
Everolimus—Nasopharyngitis—Metformin—polycystic ovary syndrome	0.00339	0.0102	CcSEcCtD
Everolimus—Abdominal distension—Metformin—polycystic ovary syndrome	0.0033	0.00995	CcSEcCtD
Everolimus—Influenza—Metformin—polycystic ovary syndrome	0.00328	0.00988	CcSEcCtD
Everolimus—Pancreatitis—Metformin—polycystic ovary syndrome	0.00321	0.00969	CcSEcCtD
Everolimus—Angina pectoris—Metformin—polycystic ovary syndrome	0.00319	0.00963	CcSEcCtD
Everolimus—Neutropenia—Metformin—polycystic ovary syndrome	0.00307	0.00924	CcSEcCtD
Everolimus—Upper respiratory tract infection—Metformin—polycystic ovary syndrome	0.00305	0.00919	CcSEcCtD
Everolimus—Infestation NOS—Metformin—polycystic ovary syndrome	0.00292	0.00881	CcSEcCtD
Everolimus—Infestation—Metformin—polycystic ovary syndrome	0.00292	0.00881	CcSEcCtD
Everolimus—Hepatobiliary disease—Metformin—polycystic ovary syndrome	0.00277	0.00834	CcSEcCtD
Everolimus—Rhinitis—Metformin—polycystic ovary syndrome	0.00263	0.00793	CcSEcCtD
Everolimus—Hepatitis—Metformin—polycystic ovary syndrome	0.00262	0.00791	CcSEcCtD
Everolimus—Hypoaesthesia—Metformin—polycystic ovary syndrome	0.00261	0.00787	CcSEcCtD
Everolimus—Oedema peripheral—Metformin—polycystic ovary syndrome	0.00259	0.00779	CcSEcCtD
Everolimus—Connective tissue disorder—Metformin—polycystic ovary syndrome	0.00258	0.00778	CcSEcCtD
Everolimus—Eye disorder—Metformin—polycystic ovary syndrome	0.00245	0.00739	CcSEcCtD
Everolimus—Flushing—Metformin—polycystic ovary syndrome	0.00244	0.00734	CcSEcCtD
Everolimus—Cardiac disorder—Metformin—polycystic ovary syndrome	0.00244	0.00734	CcSEcCtD
Everolimus—Angiopathy—Metformin—polycystic ovary syndrome	0.00238	0.00718	CcSEcCtD
Everolimus—Immune system disorder—Metformin—polycystic ovary syndrome	0.00237	0.00715	CcSEcCtD
Everolimus—Mediastinal disorder—Metformin—polycystic ovary syndrome	0.00237	0.00713	CcSEcCtD
Everolimus—Chills—Metformin—polycystic ovary syndrome	0.00235	0.0071	CcSEcCtD
Everolimus—Erythema—Metformin—polycystic ovary syndrome	0.00228	0.00689	CcSEcCtD
Everolimus—Malnutrition—Metformin—polycystic ovary syndrome	0.00228	0.00689	CcSEcCtD
Everolimus—Flatulence—Metformin—polycystic ovary syndrome	0.00225	0.00679	CcSEcCtD
Everolimus—Dysgeusia—Metformin—polycystic ovary syndrome	0.00224	0.00674	CcSEcCtD
Everolimus—Muscle spasms—Metformin—polycystic ovary syndrome	0.0022	0.00662	CcSEcCtD
Everolimus—Vision blurred—Metformin—polycystic ovary syndrome	0.00215	0.00649	CcSEcCtD
Everolimus—CYP3A4—endocrine gland—polycystic ovary syndrome	0.00214	0.0124	CbGeAlD
Everolimus—Tremor—Metformin—polycystic ovary syndrome	0.00214	0.00645	CcSEcCtD
Everolimus—Ill-defined disorder—Metformin—polycystic ovary syndrome	0.00212	0.00639	CcSEcCtD
Everolimus—Malaise—Metformin—polycystic ovary syndrome	0.00206	0.00621	CcSEcCtD
Everolimus—Syncope—Metformin—polycystic ovary syndrome	0.00205	0.00618	CcSEcCtD
Everolimus—Palpitations—Metformin—polycystic ovary syndrome	0.00202	0.00609	CcSEcCtD
Everolimus—Loss of consciousness—Metformin—polycystic ovary syndrome	0.00201	0.00605	CcSEcCtD
Everolimus—Hypertension—Metformin—polycystic ovary syndrome	0.00197	0.00595	CcSEcCtD
Everolimus—Myalgia—Metformin—polycystic ovary syndrome	0.00195	0.00586	CcSEcCtD
Everolimus—Chest pain—Metformin—polycystic ovary syndrome	0.00195	0.00586	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Metformin—polycystic ovary syndrome	0.00193	0.00582	CcSEcCtD
Everolimus—Discomfort—Metformin—polycystic ovary syndrome	0.00192	0.00579	CcSEcCtD
Everolimus—Oedema—Metformin—polycystic ovary syndrome	0.00186	0.00562	CcSEcCtD
Everolimus—Infection—Metformin—polycystic ovary syndrome	0.00185	0.00558	CcSEcCtD
Everolimus—Shock—Metformin—polycystic ovary syndrome	0.00183	0.00553	CcSEcCtD
Everolimus—Nervous system disorder—Metformin—polycystic ovary syndrome	0.00183	0.00551	CcSEcCtD
Everolimus—Thrombocytopenia—Metformin—polycystic ovary syndrome	0.00183	0.0055	CcSEcCtD
Everolimus—Skin disorder—Metformin—polycystic ovary syndrome	0.00181	0.00546	CcSEcCtD
Everolimus—Hyperhidrosis—Metformin—polycystic ovary syndrome	0.0018	0.00543	CcSEcCtD
Everolimus—Anorexia—Metformin—polycystic ovary syndrome	0.00178	0.00536	CcSEcCtD
Everolimus—Hypotension—Metformin—polycystic ovary syndrome	0.00174	0.00525	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Metformin—polycystic ovary syndrome	0.0017	0.00512	CcSEcCtD
Everolimus—Paraesthesia—Metformin—polycystic ovary syndrome	0.00167	0.00505	CcSEcCtD
Everolimus—Dyspnoea—Metformin—polycystic ovary syndrome	0.00166	0.00501	CcSEcCtD
Everolimus—Somnolence—Metformin—polycystic ovary syndrome	0.00166	0.005	CcSEcCtD
Everolimus—Dyspepsia—Metformin—polycystic ovary syndrome	0.00164	0.00495	CcSEcCtD
Everolimus—Decreased appetite—Metformin—polycystic ovary syndrome	0.00162	0.00489	CcSEcCtD
Everolimus—Gastrointestinal disorder—Metformin—polycystic ovary syndrome	0.00161	0.00485	CcSEcCtD
Everolimus—Fatigue—Metformin—polycystic ovary syndrome	0.00161	0.00485	CcSEcCtD
Everolimus—Constipation—Metformin—polycystic ovary syndrome	0.00159	0.00481	CcSEcCtD
Everolimus—Feeling abnormal—Metformin—polycystic ovary syndrome	0.00154	0.00463	CcSEcCtD
Everolimus—Gastrointestinal pain—Metformin—polycystic ovary syndrome	0.00152	0.0046	CcSEcCtD
Everolimus—Abdominal pain—Metformin—polycystic ovary syndrome	0.00147	0.00444	CcSEcCtD
Everolimus—Asthenia—Metformin—polycystic ovary syndrome	0.00134	0.00403	CcSEcCtD
Everolimus—Pruritus—Metformin—polycystic ovary syndrome	0.00132	0.00398	CcSEcCtD
Everolimus—Diarrhoea—Metformin—polycystic ovary syndrome	0.00128	0.00385	CcSEcCtD
Everolimus—Dizziness—Metformin—polycystic ovary syndrome	0.00123	0.00372	CcSEcCtD
Everolimus—Vomiting—Metformin—polycystic ovary syndrome	0.00119	0.00357	CcSEcCtD
Everolimus—Rash—Metformin—polycystic ovary syndrome	0.00118	0.00354	CcSEcCtD
Everolimus—Dermatitis—Metformin—polycystic ovary syndrome	0.00117	0.00354	CcSEcCtD
Everolimus—Headache—Metformin—polycystic ovary syndrome	0.00117	0.00352	CcSEcCtD
Everolimus—Nausea—Metformin—polycystic ovary syndrome	0.00111	0.00334	CcSEcCtD
Everolimus—MTOR—B Cell Activation—IRS1—polycystic ovary syndrome	0.000333	0.000672	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—FGF18—polycystic ovary syndrome	0.000333	0.000672	CbGpPWpGaD
Everolimus—FKBP1A—Disease—FGF18—polycystic ovary syndrome	0.000331	0.000669	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—BCL2—polycystic ovary syndrome	0.00033	0.000667	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—AKT2—polycystic ovary syndrome	0.00033	0.000666	CbGpPWpGaD
Everolimus—FKBP1A—Disease—RBP4—polycystic ovary syndrome	0.000329	0.000663	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—NRG1—polycystic ovary syndrome	0.000328	0.000662	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—AKT2—polycystic ovary syndrome	0.000327	0.00066	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—AKT2—polycystic ovary syndrome	0.000326	0.000658	CbGpPWpGaD
Everolimus—MTOR—VEGFA-VEGFR2 Pathway—VEGFA—polycystic ovary syndrome	0.000326	0.000657	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—FLT4—polycystic ovary syndrome	0.00032	0.000646	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—IRS1—polycystic ovary syndrome	0.000319	0.000643	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—GAB1—polycystic ovary syndrome	0.000317	0.000639	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—AKT2—polycystic ovary syndrome	0.000308	0.000622	CbGpPWpGaD
Everolimus—MTOR—Signaling by VEGF—VEGFA—polycystic ovary syndrome	0.000307	0.000621	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—GAB1—polycystic ovary syndrome	0.000304	0.000614	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—FSHR—polycystic ovary syndrome	0.000304	0.000613	CbGpPWpGaD
Everolimus—FKBP1A—Disease—GAB1—polycystic ovary syndrome	0.000303	0.000611	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—AKT2—polycystic ovary syndrome	0.000295	0.000595	CbGpPWpGaD
Everolimus—FKBP1A—Disease—NAMPT—polycystic ovary syndrome	0.000295	0.000595	CbGpPWpGaD
Everolimus—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—polycystic ovary syndrome	0.000295	0.000595	CbGpPWpGaD
Everolimus—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—polycystic ovary syndrome	0.000293	0.000591	CbGpPWpGaD
Everolimus—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—polycystic ovary syndrome	0.000289	0.000583	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—RACGAP1—polycystic ovary syndrome	0.000286	0.000576	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—TNRC6B—polycystic ovary syndrome	0.000283	0.000571	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—IRS2—polycystic ovary syndrome	0.000281	0.000567	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NPB—polycystic ovary syndrome	0.00028	0.000564	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—ADRA1A—polycystic ovary syndrome	0.000278	0.000561	CbGpPWpGaD
Everolimus—FKBP1A—Disease—AKR1C3—polycystic ovary syndrome	0.000275	0.000555	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—TNRC6B—polycystic ovary syndrome	0.000272	0.000549	CbGpPWpGaD
Everolimus—MTOR—IRS-mediated signalling—IL6—polycystic ovary syndrome	0.000271	0.000547	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—FST—polycystic ovary syndrome	0.000271	0.000546	CbGpPWpGaD
Everolimus—FKBP1A—Disease—TNRC6B—polycystic ovary syndrome	0.000271	0.000546	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—ADRB3—polycystic ovary syndrome	0.000267	0.00054	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—LHB—polycystic ovary syndrome	0.000264	0.000533	CbGpPWpGaD
Everolimus—MTOR—IRS-related events—IL6—polycystic ovary syndrome	0.000263	0.000532	CbGpPWpGaD
Everolimus—MTOR—IRS-related events triggered by IGF1R—IL6—polycystic ovary syndrome	0.000261	0.000527	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—GNRH1—polycystic ovary syndrome	0.000258	0.000521	CbGpPWpGaD
Everolimus—CYP3A4—Metapathway biotransformation—AKR1C1—polycystic ovary syndrome	0.000257	0.000519	CbGpPWpGaD
Everolimus—MTOR—Disease—RPL37A—polycystic ovary syndrome	0.000257	0.000519	CbGpPWpGaD
Everolimus—MTOR—IGF1R signaling cascade—IL6—polycystic ovary syndrome	0.000254	0.000513	CbGpPWpGaD
Everolimus—MTOR—Insulin receptor signalling cascade—IL6—polycystic ovary syndrome	0.000254	0.000513	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PLEKHG5—polycystic ovary syndrome	0.000253	0.00051	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—AKR1C1—polycystic ovary syndrome	0.00025	0.000505	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—ATF1—polycystic ovary syndrome	0.000249	0.000502	CbGpPWpGaD
Everolimus—MTOR—Immune System—RACGAP1—polycystic ovary syndrome	0.000248	0.000501	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—SCT—polycystic ovary syndrome	0.000248	0.0005	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—VEGFA—polycystic ovary syndrome	0.000247	0.000499	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—IRS1—polycystic ovary syndrome	0.000245	0.000495	CbGpPWpGaD
Everolimus—MTOR—Disease—HMMR—polycystic ovary syndrome	0.000244	0.000492	CbGpPWpGaD
Everolimus—CYP3A4—Biological oxidations—SULT2A1—polycystic ovary syndrome	0.00024	0.000485	CbGpPWpGaD
Everolimus—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—polycystic ovary syndrome	0.000237	0.000479	CbGpPWpGaD
Everolimus—CYP3A4—Metapathway biotransformation—SULT2A1—polycystic ovary syndrome	0.000237	0.000478	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—MTNR1B—polycystic ovary syndrome	0.000236	0.000477	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—LHCGR—polycystic ovary syndrome	0.000233	0.000471	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PTGER3—polycystic ovary syndrome	0.000233	0.000471	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—FGF18—polycystic ovary syndrome	0.000232	0.000469	CbGpPWpGaD
Everolimus—FKBP1A—Disease—TCF7L2—polycystic ovary syndrome	0.000232	0.000468	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—RBP4—polycystic ovary syndrome	0.00023	0.000465	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—TAB1—polycystic ovary syndrome	0.000229	0.000463	CbGpPWpGaD
Everolimus—MTOR—Senescence and Autophagy in Cancer—IL6—polycystic ovary syndrome	0.000229	0.000462	CbGpPWpGaD
Everolimus—FKBP1A—Disease—SLC2A4—polycystic ovary syndrome	0.000228	0.00046	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—AKT2—polycystic ovary syndrome	0.000227	0.000458	CbGpPWpGaD
Everolimus—MTOR—VEGFA-VEGFR2 Pathway—IL6—polycystic ovary syndrome	0.000225	0.000455	CbGpPWpGaD
Everolimus—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—polycystic ovary syndrome	0.000218	0.000441	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PTAFR—polycystic ovary syndrome	0.000218	0.000441	CbGpPWpGaD
Everolimus—FKBP1A—Disease—PRL—polycystic ovary syndrome	0.000217	0.000439	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—YAP1—polycystic ovary syndrome	0.000215	0.000434	CbGpPWpGaD
Everolimus—CYP3A4—Biological oxidations—CYP11A1—polycystic ovary syndrome	0.000213	0.000429	CbGpPWpGaD
Everolimus—MTOR—Signaling by VEGF—IL6—polycystic ovary syndrome	0.000213	0.000429	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—GAB1—polycystic ovary syndrome	0.000212	0.000428	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—ADRA1D—polycystic ovary syndrome	0.000212	0.000428	CbGpPWpGaD
Everolimus—MTOR—Signaling by Insulin receptor—IL6—polycystic ovary syndrome	0.000211	0.000426	CbGpPWpGaD
Everolimus—CYP3A4—Metapathway biotransformation—CYP11A1—polycystic ovary syndrome	0.00021	0.000423	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—ADRA1B—polycystic ovary syndrome	0.000206	0.000416	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—INSR—polycystic ovary syndrome	0.000203	0.000409	CbGpPWpGaD
Everolimus—MTOR—Immune System—FGF18—polycystic ovary syndrome	0.000202	0.000408	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—INHBB—polycystic ovary syndrome	0.000201	0.000406	CbGpPWpGaD
Everolimus—MTOR—Disease—AKR1C1—polycystic ovary syndrome	0.000201	0.000405	CbGpPWpGaD
Everolimus—CYP3A4—Metapathway biotransformation—AKR1C3—polycystic ovary syndrome	0.000198	0.0004	CbGpPWpGaD
Everolimus—CYP3A4—Biological oxidations—CYP17A1—polycystic ovary syndrome	0.000198	0.000399	CbGpPWpGaD
Everolimus—CYP3A4—Metapathway biotransformation—CYP17A1—polycystic ovary syndrome	0.000195	0.000394	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—AKR1C3—polycystic ovary syndrome	0.000193	0.000389	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—TNRC6B—polycystic ovary syndrome	0.00019	0.000383	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PGR—polycystic ovary syndrome	0.000188	0.000379	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PDE3B—polycystic ovary syndrome	0.000188	0.000379	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—NRG1—polycystic ovary syndrome	0.000187	0.000377	CbGpPWpGaD
Everolimus—MTOR—Disease—FGF18—polycystic ovary syndrome	0.000186	0.000376	CbGpPWpGaD
Everolimus—MTOR—Disease—RBP4—polycystic ovary syndrome	0.000185	0.000373	CbGpPWpGaD
Everolimus—MTOR—Immune System—GAB1—polycystic ovary syndrome	0.000184	0.000372	CbGpPWpGaD
Everolimus—FKBP1A—Disease—NCOR1—polycystic ovary syndrome	0.000182	0.000368	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—IL6—polycystic ovary syndrome	0.000181	0.000365	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—NRG1—polycystic ovary syndrome	0.00018	0.000362	CbGpPWpGaD
Everolimus—FKBP1A—Disease—NRG1—polycystic ovary syndrome	0.000179	0.000361	CbGpPWpGaD
Everolimus—CYP3A4—Phase 1 - Functionalization of compounds—POMC—polycystic ovary syndrome	0.000177	0.000357	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PLAT—polycystic ovary syndrome	0.000174	0.000352	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—GHRL—polycystic ovary syndrome	0.000174	0.000352	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling of activated FGFR—IL6—polycystic ovary syndrome	0.000173	0.000349	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—FSHR—polycystic ovary syndrome	0.000171	0.000345	CbGpPWpGaD
Everolimus—MTOR—Disease—GAB1—polycystic ovary syndrome	0.00017	0.000344	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—IL6—polycystic ovary syndrome	0.00017	0.000343	CbGpPWpGaD
Everolimus—MTOR—Immune System—CAMK2D—polycystic ovary syndrome	0.000167	0.000338	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—ATF1—polycystic ovary syndrome	0.000166	0.000336	CbGpPWpGaD
Everolimus—MTOR—Disease—NAMPT—polycystic ovary syndrome	0.000166	0.000335	CbGpPWpGaD
Everolimus—MTOR—Immune System—TNRC6B—polycystic ovary syndrome	0.000165	0.000333	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—IL6—polycystic ovary syndrome	0.000162	0.000328	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—TCF7L2—polycystic ovary syndrome	0.000162	0.000328	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—IL6—polycystic ovary syndrome	0.000162	0.000326	CbGpPWpGaD
Everolimus—FKBP1A—Disease—MTHFR—polycystic ovary syndrome	0.000161	0.000325	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—IL6—polycystic ovary syndrome	0.000161	0.000325	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—RACGAP1—polycystic ovary syndrome	0.000161	0.000324	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—IRS2—polycystic ovary syndrome	0.00016	0.000323	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—CRP—polycystic ovary syndrome	0.00016	0.000323	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—IL6—polycystic ovary syndrome	0.00016	0.000323	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—VEGFA—polycystic ovary syndrome	0.000158	0.000319	CbGpPWpGaD
Everolimus—CYP3A4—Biological oxidations—CYP19A1—polycystic ovary syndrome	0.000156	0.000316	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—ADRA1A—polycystic ovary syndrome	0.000156	0.000315	CbGpPWpGaD
Everolimus—MTOR—Disease—AKR1C3—polycystic ovary syndrome	0.000155	0.000312	CbGpPWpGaD
Everolimus—CYP3A4—Metapathway biotransformation—CYP19A1—polycystic ovary syndrome	0.000154	0.000312	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—IRS2—polycystic ovary syndrome	0.000154	0.00031	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—NGFR—polycystic ovary syndrome	0.000154	0.00031	CbGpPWpGaD
Everolimus—FKBP1A—Disease—IRS2—polycystic ovary syndrome	0.000153	0.000309	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—FST—polycystic ovary syndrome	0.000152	0.000307	CbGpPWpGaD
Everolimus—MTOR—Disease—TNRC6B—polycystic ovary syndrome	0.000152	0.000307	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PRL—polycystic ovary syndrome	0.000152	0.000307	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—IL6—polycystic ovary syndrome	0.000151	0.000304	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—IL6—polycystic ovary syndrome	0.000151	0.000304	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—IL6—polycystic ovary syndrome	0.000151	0.000304	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—ADRB3—polycystic ovary syndrome	0.00015	0.000304	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—IL6—polycystic ovary syndrome	0.000149	0.000301	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—LHB—polycystic ovary syndrome	0.000149	0.0003	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—IL6—polycystic ovary syndrome	0.000148	0.000299	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—IL6—polycystic ovary syndrome	0.000147	0.000297	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—GNRH1—polycystic ovary syndrome	0.000145	0.000293	CbGpPWpGaD
Everolimus—MTOR—Immune System—ATF1—polycystic ovary syndrome	0.000145	0.000292	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—ADRB2—polycystic ovary syndrome	0.000144	0.000291	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—AKR1C1—polycystic ovary syndrome	0.000141	0.000284	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—IRS1—polycystic ovary syndrome	0.00014	0.000282	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—SCT—polycystic ovary syndrome	0.000139	0.000281	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—IRS1—polycystic ovary syndrome	0.000134	0.000271	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—GNAS—polycystic ovary syndrome	0.000134	0.00027	CbGpPWpGaD
Everolimus—FKBP1A—Disease—IRS1—polycystic ovary syndrome	0.000134	0.00027	CbGpPWpGaD
Everolimus—MTOR—Immune System—TAB1—polycystic ovary syndrome	0.000134	0.00027	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—IL6—polycystic ovary syndrome	0.000133	0.000269	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—MTNR1B—polycystic ovary syndrome	0.000133	0.000268	CbGpPWpGaD
Everolimus—MTOR—Immune System—PRL—polycystic ovary syndrome	0.000132	0.000267	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—FGF18—polycystic ovary syndrome	0.000131	0.000264	CbGpPWpGaD
Everolimus—MTOR—Disease—TCF7L2—polycystic ovary syndrome	0.00013	0.000263	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—RBP4—polycystic ovary syndrome	0.000129	0.000261	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—AKT2—polycystic ovary syndrome	0.000129	0.000261	CbGpPWpGaD
Everolimus—MTOR—Disease—SLC2A4—polycystic ovary syndrome	0.000128	0.000259	CbGpPWpGaD
Everolimus—FKBP1A—Disease—INS—polycystic ovary syndrome	0.000128	0.000258	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—NCOR1—polycystic ovary syndrome	0.000128	0.000257	CbGpPWpGaD
Everolimus—CYP3A4—Biological oxidations—CYP1A1—polycystic ovary syndrome	0.000126	0.000255	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—NRG1—polycystic ovary syndrome	0.000125	0.000253	CbGpPWpGaD
Everolimus—CYP3A4—Metapathway biotransformation—CYP1A1—polycystic ovary syndrome	0.000124	0.000251	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—AKT2—polycystic ovary syndrome	0.000124	0.000251	CbGpPWpGaD
Everolimus—FKBP1A—Disease—AKT2—polycystic ovary syndrome	0.000124	0.00025	CbGpPWpGaD
Everolimus—MTOR—Disease—PRL—polycystic ovary syndrome	0.000122	0.000247	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—YAP1—polycystic ovary syndrome	0.000121	0.000244	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—GAB1—polycystic ovary syndrome	0.000119	0.000241	CbGpPWpGaD
Everolimus—FKBP1A—Disease—SERPINE1—polycystic ovary syndrome	0.000118	0.000237	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—INSR—polycystic ovary syndrome	0.000114	0.00023	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—BCL2—polycystic ovary syndrome	0.000113	0.000228	CbGpPWpGaD
Everolimus—MTOR—Immune System—IL18—polycystic ovary syndrome	0.000111	0.000225	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—NMNAT3—polycystic ovary syndrome	0.000111	0.000224	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—IL6—polycystic ovary syndrome	0.000109	0.000221	CbGpPWpGaD
Everolimus—MTOR—Immune System—NRG1—polycystic ovary syndrome	0.000109	0.00022	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—AKR1C3—polycystic ovary syndrome	0.000108	0.000219	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—IRS2—polycystic ovary syndrome	0.000107	0.000216	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TNRC6B—polycystic ovary syndrome	0.000107	0.000215	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PGR—polycystic ovary syndrome	0.000106	0.000213	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—LEP—polycystic ovary syndrome	0.000105	0.000212	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—IL6—polycystic ovary syndrome	0.000103	0.000207	CbGpPWpGaD
Everolimus—MTOR—Disease—NCOR1—polycystic ovary syndrome	0.000102	0.000207	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—SUOX—polycystic ovary syndrome	0.000101	0.000205	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—LPCAT2—polycystic ovary syndrome	0.000101	0.000205	CbGpPWpGaD
Everolimus—MTOR—Disease—NRG1—polycystic ovary syndrome	0.000101	0.000203	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PLAT—polycystic ovary syndrome	9.81e-05	0.000198	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—GHRL—polycystic ovary syndrome	9.81e-05	0.000198	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ISYNA1—polycystic ovary syndrome	9.43e-05	0.00019	CbGpPWpGaD
Everolimus—CYP3A4—Biological oxidations—POMC—polycystic ovary syndrome	9.4e-05	0.00019	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—IRS1—polycystic ovary syndrome	9.36e-05	0.000189	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—ATF1—polycystic ovary syndrome	9.36e-05	0.000189	CbGpPWpGaD
Everolimus—MTOR—Immune System—CRP—polycystic ovary syndrome	9.33e-05	0.000188	CbGpPWpGaD
Everolimus—MTOR—Immune System—IRS2—polycystic ovary syndrome	9.33e-05	0.000188	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TCF7L2—polycystic ovary syndrome	9.13e-05	0.000184	CbGpPWpGaD
Everolimus—MTOR—Disease—MTHFR—polycystic ovary syndrome	9.05e-05	0.000183	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—POMC—polycystic ovary syndrome	9.01e-05	0.000182	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—INS—polycystic ovary syndrome	8.96e-05	0.000181	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—IGF1—polycystic ovary syndrome	8.67e-05	0.000175	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—AKT2—polycystic ovary syndrome	8.66e-05	0.000175	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NGFR—polycystic ovary syndrome	8.64e-05	0.000174	CbGpPWpGaD
Everolimus—MTOR—Disease—IRS2—polycystic ovary syndrome	8.61e-05	0.000174	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PRL—polycystic ovary syndrome	8.56e-05	0.000173	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—SERPINE1—polycystic ovary syndrome	8.23e-05	0.000166	CbGpPWpGaD
Everolimus—MTOR—Immune System—IRS1—polycystic ovary syndrome	8.14e-05	0.000164	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—ADRB2—polycystic ovary syndrome	8.12e-05	0.000164	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—TEAD2—polycystic ovary syndrome	8.02e-05	0.000162	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—AKR1C2—polycystic ovary syndrome	8.02e-05	0.000162	CbGpPWpGaD
Everolimus—MTOR—Immune System—AKT2—polycystic ovary syndrome	7.54e-05	0.000152	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—GNAS—polycystic ovary syndrome	7.53e-05	0.000152	CbGpPWpGaD
Everolimus—MTOR—Disease—IRS1—polycystic ovary syndrome	7.52e-05	0.000152	CbGpPWpGaD
Everolimus—MTOR—Disease—INS—polycystic ovary syndrome	7.2e-05	0.000145	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NCOR1—polycystic ovary syndrome	7.17e-05	0.000145	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NRG1—polycystic ovary syndrome	7.04e-05	0.000142	CbGpPWpGaD
Everolimus—MTOR—Disease—AKT2—polycystic ovary syndrome	6.96e-05	0.00014	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PNPLA2—polycystic ovary syndrome	6.72e-05	0.000136	CbGpPWpGaD
Everolimus—MTOR—Disease—SERPINE1—polycystic ovary syndrome	6.61e-05	0.000133	CbGpPWpGaD
Everolimus—MTOR—Immune System—BCL2—polycystic ovary syndrome	6.58e-05	0.000133	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—SRD5A1—polycystic ovary syndrome	6.37e-05	0.000129	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—STAR—polycystic ovary syndrome	6.08e-05	0.000123	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IRS2—polycystic ovary syndrome	6.03e-05	0.000122	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—LEP—polycystic ovary syndrome	5.9e-05	0.000119	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—IL6—polycystic ovary syndrome	5.85e-05	0.000118	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—VEGFA—polycystic ovary syndrome	5.66e-05	0.000114	CbGpPWpGaD
Everolimus—FKBP1A—Disease—IL6—polycystic ovary syndrome	5.59e-05	0.000113	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—HMMR—polycystic ovary syndrome	5.42e-05	0.000109	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IRS1—polycystic ovary syndrome	5.26e-05	0.000106	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—HSD3B1—polycystic ovary syndrome	5.17e-05	0.000104	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—POMC—polycystic ovary syndrome	5.07e-05	0.000102	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—INS—polycystic ovary syndrome	5.04e-05	0.000102	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IGF1—polycystic ovary syndrome	4.88e-05	9.84e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—AKT2—polycystic ovary syndrome	4.87e-05	9.84e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—LHB—polycystic ovary syndrome	4.71e-05	9.51e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—SERPINE1—polycystic ovary syndrome	4.63e-05	9.35e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—HSD3B2—polycystic ovary syndrome	4.61e-05	9.3e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—AKR1C1—polycystic ovary syndrome	4.46e-05	9.01e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—SULT2A1—polycystic ovary syndrome	4.11e-05	8.29e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—RRM2—polycystic ovary syndrome	3.98e-05	8.03e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—IL6—polycystic ovary syndrome	3.92e-05	7.91e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—YAP1—polycystic ovary syndrome	3.83e-05	7.74e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—NAMPT—polycystic ovary syndrome	3.68e-05	7.43e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CYP11A1—polycystic ovary syndrome	3.64e-05	7.34e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—AKR1C3—polycystic ovary syndrome	3.43e-05	6.93e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—IL6—polycystic ovary syndrome	3.41e-05	6.88e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CYP17A1—polycystic ovary syndrome	3.38e-05	6.83e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—VEGFA—polycystic ovary syndrome	3.19e-05	6.43e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—IL6—polycystic ovary syndrome	3.15e-05	6.35e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—TH—polycystic ovary syndrome	2.93e-05	5.91e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—SLC2A4—polycystic ovary syndrome	2.85e-05	5.75e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CYP19A1—polycystic ovary syndrome	2.68e-05	5.4e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GNAS—polycystic ovary syndrome	2.39e-05	4.82e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—NCOR1—polycystic ovary syndrome	2.28e-05	4.59e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IL6—polycystic ovary syndrome	2.2e-05	4.45e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CYP1A1—polycystic ovary syndrome	2.16e-05	4.35e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—MTHFR—polycystic ovary syndrome	2.01e-05	4.06e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PPARG—polycystic ovary syndrome	1.63e-05	3.29e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—POMC—polycystic ovary syndrome	1.61e-05	3.25e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—INS—polycystic ovary syndrome	1.6e-05	3.23e-05	CbGpPWpGaD
